416 related articles for article (PubMed ID: 26514968)
1. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.
Lisbeth P; Vincent H; Kristof M; Bernard S; Manuel M; Hugo N
Eur J Clin Pharmacol; 2016 Feb; 72(2):175-84. PubMed ID: 26514968
[TBL] [Abstract][Full Text] [Related]
2. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
van der Weide K; van der Weide J
J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
[TBL] [Abstract][Full Text] [Related]
4. Influence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol.
Linnet K; Wiborg O
Ther Drug Monit; 1996 Dec; 18(6):629-34. PubMed ID: 8946657
[TBL] [Abstract][Full Text] [Related]
5. Impact of CYP2D6 Polymorphism on Steady-State Plasma Levels of Risperidone and 9-Hydroxyrisperidone in Thai Children and Adolescents with Autism Spectrum Disorder.
Vanwong N; Ngamsamut N; Medhasi S; Puangpetch A; Chamnanphon M; Tan-Kam T; Hongkaew Y; Limsila P; Sukasem C
J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):185-191. PubMed ID: 26780783
[TBL] [Abstract][Full Text] [Related]
6. Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype.
Molden E; Waade RB; Hoff M; Haslemo T
Basic Clin Pharmacol Toxicol; 2016 Nov; 119(5):470-475. PubMed ID: 27145399
[TBL] [Abstract][Full Text] [Related]
7. Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes.
Kneller LA; Abad-Santos F; Hempel G
Clin Pharmacokinet; 2020 Jan; 59(1):51-65. PubMed ID: 31359271
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
Jukic MM; Smith RL; Haslemo T; Molden E; Ingelman-Sundberg M
Lancet Psychiatry; 2019 May; 6(5):418-426. PubMed ID: 31000417
[TBL] [Abstract][Full Text] [Related]
9. Impact of CYP2D6 on serum concentrations of flupentixol, haloperidol, perphenazine and zuclopenthixol.
Waade RB; Solhaug V; Høiseth G
Br J Clin Pharmacol; 2021 May; 87(5):2228-2235. PubMed ID: 33118660
[TBL] [Abstract][Full Text] [Related]
10. Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype.
Hendset M; Molden E; Knape M; Hermann M
Ther Drug Monit; 2014 Feb; 36(1):80-5. PubMed ID: 24232129
[TBL] [Abstract][Full Text] [Related]
11. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole.
Hendset M; Hermann M; Lunde H; Refsum H; Molden E
Eur J Clin Pharmacol; 2007 Dec; 63(12):1147-51. PubMed ID: 17828532
[TBL] [Abstract][Full Text] [Related]
12. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
13. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.
Kubo M; Koue T; Inaba A; Takeda H; Maune H; Fukuda T; Azuma J
Drug Metab Pharmacokinet; 2005 Feb; 20(1):55-64. PubMed ID: 15770075
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP2D6 Metabolizer Status on Risperidone and Paliperidone Tolerability in Children and Adolescents.
Kanu AA; Johnston MM; Poweleit EA; Vaughn SE; Strawn JR; Ramsey LB
J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):34-41. PubMed ID: 38377522
[No Abstract] [Full Text] [Related]
15. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
[TBL] [Abstract][Full Text] [Related]
17. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
[TBL] [Abstract][Full Text] [Related]
18. Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: A systematic review and meta-analysis.
Zhang X; Xiang Q; Zhao X; Ma L; Cui Y
J Clin Pharm Ther; 2019 Apr; 44(2):163-173. PubMed ID: 30565279
[TBL] [Abstract][Full Text] [Related]
19. Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.
Vandenberghe F; Guidi M; Choong E; von Gunten A; Conus P; Csajka C; Eap CB
Clin Pharmacokinet; 2015 Dec; 54(12):1259-72. PubMed ID: 26129906
[TBL] [Abstract][Full Text] [Related]
20. Optimization of maintenance therapy of Risperidone with CYP2D6 genetic polymorphisms through an extended translational framework-based prediction of target occupancies/clinical outcomes.
Li HQ; Xu JY; Gao YY; Jin L
Pharmacol Res; 2018 Nov; 137():135-147. PubMed ID: 30281999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]